Articles tagged with: Ixazomib
Press Releases»
− Oral Data Presentation to be Featured in “Highlights of ASH” −
New Orleans, LA & Osaka, Japan (Press Release) - Takeda Pharmaceutical Company Limited (TSE:4502) today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The investigators reported a combined complete response and very good partial response (CR+VGPR) rate of 76 percent (46/62) and a 94 percent overall response rate (ORR; 58/62 ≥ partial response). Stringent complete response (sCR) was reached in 75 percent of patients …
News»
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in the form …
News»
The Beacon continues today with its ‘ASH preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December.
Abstracts for the ASH presentations are now available, although many contain preliminary information that will be updated at the meeting.
The Beacon’s ASH preview articles are intended to highlight the meeting's most interesting myeloma-related studies.
The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest potential myeloma therapies just starting out in clinical trials. Further previews will …
News»
This year’s Congress of the European Hematology Association (EHA) is currently being held in Stockholm. It started earlier this week and will run through Sunday, June 16.
A substantial amount of myeloma-related research will be presented during the EHA meeting during both oral presentations and poster presentations.
This article summarizes some of the important myeloma-related findings that are expected to be presented during poster sessions today and tomorrow. A previous article covered the key findings that will be presented during oral presentations.
The studies covered in this article are primarily ones …
News»
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting.
Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did the research at the meeting represent a major step forward for myeloma patients, or …
News»
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.
Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday's oral presentation session. A later article will cover the findings from the afternoon poster session.
The content in our daily updates is based on the …
NewsFlash »
Antidepressant Demonstrates Anti-Myeloma Activity - Results of a preclinical study conducted in China indicate that the antidepressant amitriptyline (Elavil) may have anti-myeloma activity. Amitriptyline is an older drug, first approved for use in the United States in the early 1960s. It belongs to a class of drugs known as tricyclic antidepressants. Myeloma patients may be aware of the drug because it sometimes is prescribed as a treatment for peripheral neuropathy (pain, tingling, and loss of sensation in the extremities due to nerve damage). In the recent Chinese study, researchers found that orally administered amitriptyline significantly reduced the growth of myeloma cells in mice implanted with either mouse or human myeloma cells. As a result, the drug substantially extended the survival of the mice with the myeloma cells. The researchers also found that combining amitriptyline with Velcade (bortezomib) had a greater anti-myeloma effect than would have been expected given the anti-myeloma effect of each individual drug on its own. For more information, please see the study in the journal Anti-Cancer Drugs (abstract).
Phase 3 Clinical Trial To Study Ixazomib Combination In Newly Diagnosed Multiple Myeloma Patients – The pharmaceutical company Millennium has launched a Phase 3 trial of its investigational drug ixazomib (MLN9708) in newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation. The study, which will be carried out in North America and Europe, will investigate the efficacy and safety of ixazomib in combination with Revlimid (lenalidomide) and dexamethasone (Decadron). Ixazomib is an oral drug that belongs to the same class of drugs as Velcade and Kyprolis (carfilzomib), called proteasome inhibitors. In recent Phase 1/2 clinical trials, ixazomib showed promise as a single agent as well as in combination with Revlimid and dexamethasone in both newly diagnosed and relapsed/refractory myeloma patients (see related Beacon news). For more information, please see the Millennium press release and the clinical trial description.
Human Cytomegalovirus Virus Reactivation After Donor Transplant Does Not Impact Survival In Myeloma Patients – The human cytomegalovirus virus (HCMV) is a type of herpes virus which infects over half the U.S. population. The virus is usually dormant, but if it is reactivated, it can result in eye or lung infections which, if they occur in patients who have received a donor stem cell transplant, can have serious consequences, including death. The results of a recent French study show that myeloma patients who carry HCMV are at high risk of virus reactivation after reduced-intensity donor stem cell transplantation, irrespective of whether the donor also carried the virus. Patients’ whose donors carried HCMV were also at risk of virus reactivation after transplantation. Another factor that contributed to virus reactivation was if the patient, within 100 days of their transplant, developed graft-versus-host disease (a potentially serious side effect of donor stem cell transplantation in which donor immune system cells attack the patient's cells). The French researchers also found, however, that virus reactivation did not negatively impact post-transplant outcomes, such as progression-free and overall survival. In fact, there was a trend toward better outcomes for patients who were at higher risk of virus reactivation. For more information, please see the study in the Mediterranean Journal of Hematology and Infectious Diseases (full text).
LLS Teleconference On Myeloma Treatment And Side Effect Management – On June 3, the Leukemia & Lymphoma Society (LLS) will sponsor a free teleconference call about the treatment of multiple myeloma and management of side effects. Dr. Vincent Rajkumar from the Mayo Clinic will lead the program, which runs from noon to 1:30 p.m. Eastern Time. Dr. Rajkumar will speak about current and emerging myeloma treatments, the role of clinical trials in the development of myeloma treatments, and the importance of communication between patient and provider about treatment-related side effects and management of them. For more information or to register, please see the LLS website.